Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names


Shareholder links

Our website ranking of MPL: rating 4
(4 out of 5)



Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000MPL3
Address: Level 6, 720 Bourke Street, DOCKLANDS, VIC, AUSTRALIA, 3008
Tel:  03 8622 5000

Date first listed: 25/11/2014

Sector: Insurance Industry Group: XFJ

News & Events

Expand this box to read and print

The suspension of trading in the securities of Medibank Private Limited will be lifted immediately following the release by MPL of its announcement "˜Medibank cybercrime, business and FY23 outlook update'.


To date, Medibank's IT systems have not been encrypted by ransomware. Normal business operations have been maintained with customers continuing to access health services. Medibank has prioritised preventing further unauthorised entry to our IT network and is continuing to monitor for any further suspicious activity. As a result of the cybercrime event, Medibank is updating the FY23 outlook. Given the uncertain impact of this cybercrime event, Medibank is withdrawing its FY23 outlook for policyholder growth and will provide a further update at the 1H23 results. Underlying net claims expense per resident policy unit continues to track below the FY23 outlook of 2.3%. This has resulted in further permanent net claims savings due to COVID-19 of approximately $62 million and these savings will offset the cost of the deferral of premium increases for Medibank and ahm customers to 16 January 2023. Management expense productivity initiatives continue in line with the FY23 outlook and our expectation for inflation remains unchanged. APRA released the final private health insurance capital standards that will take effect from 1 July 2023, and the company continues to expect the implementation of these standards will not negatively impact our capital position. The company currently estimates $25 million-$35 million pre-tax non-recurring costs will impact earnings in 1H23. These non-recurring costs do not include further potential customer and other remediation, regulatory or litigation related costs.


Medibank provides an update on the cybercrime event. Medibank has received a series of additional files from the criminal. It is too soon to determine the full extent of the customer data that have been stolen. The company is still in the process of analysing what they had received to understand the total number of customers impacted and specifically which information has been stolen. Medibank is assisting the AFP in its ongoing investigation. The company will announce a comprehensive support package and will also defer premium increases for Medibank and ahm customers until 16 January 2023. Medibank continues to work with specialised cyber security firms, the Australian Cyber Security Centre (ACSC) and government stakeholders.


The securities of Medibank Private Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MPL, pending the release of an announcement regarding the cyber incident announced on 13 October 2022.


listed entity carried for record purposes only



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    26/02/2024Linda Nicholls5,400$3.650$19,710
    22/03/2022Gerard Dalbosco48,400$3.110$150,524
    26/08/2020Michael Wilkins40,987$2.810$115,165
    20/05/2020Anna Bligh5,300$2.800$14,840
    14/05/2020Tracey Batten15,715$2.850$44,788

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Michael WilkinsChairman25/05/2017
    David KoczkarCEO17/05/2021
    Mark RogersCFO21/11/2016
    Kathryn FaggNon Exec Director31/03/2022
    David FaganNon Exec Director25/11/2014
    Tracey BattenNon Exec Director28/08/2017
    Peter EveringhamNon Exec Director31/03/2022
    Linda NichollsNon Exec Director25/11/2014
    Jay WeatherillNon Exec Director18/03/2024
    Gerard DalboscoNon Exec Director21/05/2021
    Carolyn RamsayCompany Secretary

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Anna BlighNon Exec Director25/11/201422/11/2023
    Peter HodgettNon Exec Director25/11/201418/11/2021
    Christine O'ReillyNon Exec Director25/11/201418/11/2021
    Craig DrummondManaging Director, CEO04/07/201630/06/2021
    Elizabeth AlexanderNon Exec Chairman25/11/201430/09/2020
    Cherell HirstNon Exec Director25/11/201428/08/2017
    Tom ExtonCFO14/09/201621/11/2016
    Paul KoppelmanCFO25/11/201414/09/2016
    George SavvidesManaging Director, CEO25/11/201401/04/2016

    Date of first appointment, title may have changed.